Cantor Fitzgerald raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “an Overweight”. The rating was released on March 08, 2021. The research report from Needham has reiterated the stock to Buy, with a price target set at $15. The stock was reiterated by H.C. Wainwright, who disclosed in a research note on August 06, 2019, to Buy and set the price objective to $17. In their research brief published July 11, 2019, H.C. Wainwright analysts reiterated the Akebia Therapeutics Inc. stock to Buy with a price target of $21.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Akebia Therapeutics Inc. (NASDAQ:AKBA) dipped -2.65% to close Wednesday’s market session at $2.57, lower as compared to yesterday’s close. The stock price fluctuated between $2.53 and $2.725 throughout the trading session with the volume trading being 3664187 shares, which represented a significant variation when compared to the three months average volume of 3.94 million shares. The firm’s stock price fluctuated 3.63% within the last five trades and -22.82% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -44.37% in the last 6 months and -21.88% was subtracted to its value over the previous 3 months. AKBA stock is trading at a margin of -5.67%, -21.35% and -20.93% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, AKBA deals in the Healthcare domain. The stock is trading -77.18 percent below its 52-week high and 22.97 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -33.62. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Akebia Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $430.99 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1.66 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.85, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.50 percent of Akebia Therapeutics Inc. shares are owned by insiders, and 64.70 percent are held by financial institutions. GILMAN STEVEN C, the Director at Akebia Therapeutics Inc. (AKBA) has sold 4,567 shares of firm on Jun 07 at a price of $3.32 against the total amount of $15163.0. In another inside trade, Butler John P., CEO and President of Akebia Therapeutics Inc. (NASDAQ:AKBA) sold 49,990 shares of the firm on Mar 01 for a total worth of $0.17 million at a price of $3.40. An inside trade which took place on Mar 01, SVP, Chief Operating Officer of Akebia Therapeutics Inc. Dahan Michel sold 14,547 shares of firm against total price of $49403.0 at the cost of $3.40 per share.